Salarius (SLRX) Total Debt to Capital

The market for epigenetic therapies for rare oncological diseases is currently in the early trial stage amid high demand from clinics. A retrospective of Salarius Pharmaceuticals (SLRX) share prices shows that the separate_debt_total_eq metric is 0.00. The business focuses on developing drugs for adults and children with Ewing sarcoma, targeting the global solid tumor market; however, operations are subject to the risks of trial failure and fierce competition.

For a fundamental valuation of Salarius Pharmaceuticals (SLRX), understanding the balance between debt load and equity is critical. This indicator measures the proportion of borrowed funds within the capital structure, while the shifting ratio of financial debt to equity demonstrates the company's ability to fund costly clinical trials for oncology drugs without risking bankruptcy due to excessive leverage.